# A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Source: https://onco.cc/trials/nct07054190/  
OnCo record `nct07054190` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Inavolisib, Ribociclib and Giredestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer is a phase 2 interventional study registered as NCT07054190 by Hoffmann-La Roche, with 120 participants planned, started 2025-09-09 and due to reach its primary completion in 2027-07-31. Interventions recorded: Inavolisib, Ribociclib, Letrozole and Giredestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07054190
- Phase: 2
- Setting: A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07054190: https://clinicaltrials.gov/study/NCT07054190

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Giredestrant](https://onco.cc/drugs/giredestrant/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07054190.json